New hope for first sickle cell pain crises treatment in 20 years

Data presented at the 58th American Society of Hematology (ASH) Annual Meeting has offered hope that the first new sickle cell-related pain crises (SCPC) option for 20 years could be on its way.

Results from the Phase II SUSTAIN study show that SEG101 (crizanlizumab, formerly SelG1), an anti-P-selectin antibody from Swiss pharma giant Novartis (NOVN: VX), reduced the median annual rate of SCPC by 45.3% compared to placebo in patients with or without hydroxyurea therapy.

"Patients have long been in need of a new therapy for treatment of SCPC"